Evidence map›Paper›PMID 35754606›Full record

ReviewProceedings (Baylor University. Medical Center)2022

COVID-19-from emerging global threat to ongoing pandemic crisis.

Karen B Brust, Vinayika Papineni, Cristie Columbus, Alejandro C Arroliga

Abstract readReview
In one paragraph

Review in Proceedings (Baylor University. Medical Center), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Karen B BrustDivision of Infectious Disease, Department of Internal Medicine, Baylor Scott & White Medical Center - Temple, Temple, Texas.
Vinayika PapineniTexas A&M Health Science Center, Texas A&M University, Austin, Texas.
Cristie ColumbusDivision of Infectious Diseases, Department of Internal Medicine, Baylor University Medical Center, Dallas, Texas.ORCID https://orcid.org/0000-0001-5859-4786
Alejandro C ArroligaDivision of Pulmonary and Critical Care and Sleep Medicine, Department of Internal Medicine, Baylor Scott and White Medical Center - Temple, Temple, Texas.ORCID https://orcid.org/0000-0002-7245-2159

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In December 2019, China witnessed the emergence of a novel coronavirus, SARS-CoV-2. Its ability to spread quickly made it a global pandemic. The United States has been greatly affected, with more than 980,000 lives lost so far. Diagnosis is made primarily through nasopharyngeal swab for polymerase chain reaction. Point-of-care testing by antigen is less sensitive and specific and may require polymerase chain reaction confirmation. Management of the COVID-19 patient remains largely supportive. Steroids are now a therapy mainstay if the patient is hypoxic. Direct antivirals, such as nirmatrelvir/ritonavir, remdesivir, or molnupirivir, can be used if certain criteria are met. SARS-CoV-2 is transmitted primarily by inhalation of large droplets, though transmission by aerosolization may occur, particularly via certain procedures. In the hospital setting, use of personal protective equipment for the care of COVID-19 patients has largely remained the same, with full use of gowns, gloves, respirators, and eye protection. Inadequate supply at the start of the pandemic required innovative ways to reprocess and extend the use of personal protective equipment. Three vaccines are now available in the US, all with excellent efficacy against severe disease and hospitalization, though booster doses are needed to bolster waning antibody levels. The possibility of emerging variants continues to remain a threat to control of the pandemic. The leader of the World Health Organization, Dr. Tedros, has stated, "The pandemic will not be over anywhere until it's over everywhere."

Indexed as

CoronavirusCOVID-19infection controlinfectious diseasespandemic

Identifiers

PMID35754606
PMCPMC9196727

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.